Coronavirus
AstraZeneca Requests Emergency Use Authorization of a Coronavirus Antibody Drug
AstraZeneca said on Tuesday that it has submitted a request for emergency use authorization of an antibody drug designed to help prevent symptomatic COVID-19.
The antibody therapy, called AZD7442, provides “significant reduction” in the risk of developing COVID-19 and could provide another protective measure for vulnerable populations, including the immunocompromised, against the deadly disease, the company said in a statement
In its application to the Food and Drug Administration (FDA), AstraZeneca cited data from a trial showing the drug was 77 percent effective at thwarting symptomatic COVID-19. More than three-quarters of the tested population were immunocompromised or had other comorbidities associated with serious illness.
